Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
Status:
Not yet recruiting
Trial end date:
2025-08-30
Target enrollment:
Participant gender:
Summary
This clinical trial plans to assess to what extent the on-treatment circulating tumor DNA
(ctDNA) can predict the subset of patients with NSCLC who will respond to immunotherapy
treatment only and which patients will need both immunotherapy and chemotherapy modalities
for their treatment regimen.